Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. 3 Nature Aging | VOL 1 | July 2021 | p. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Nov 24 2021.

Patients 98

Patients Education Marijuana Therapy 98

Veriheal

AUGUST 31, 2020

Data shows that Hispanic Americans are more interested in using cannabis and CBD for wellness than other groups and “is believed to be in part due to the connections between the Hispanic community and nature.” Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

The Cannigma

JANUARY 13, 2023

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

OCTOBER 1, 2021

Mack will present an overview of Virpax and take part in a fireside chat moderated by Noble Capital Markets senior equity research analyst, Gregory Aurand at the Pain Management Virtual Investor Forum on Thursday, October 7, 2021 at 9:00 a.m. Eastern time. www.youtube.com/channelchek. About Virpax Pharmaceuticals. About Channelchek.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 About Virpax Pharmaceuticals.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Data collection.

Research and Development 52

Research and Development Medicine Access Media 52